This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Emergent BioSolutions, Inc.
Drug Names(s): UV-4
UV-4B is a glycobiology antiviral agent. UV-4 is derived from a class of compounds known as iminosugars.
Iminosugar molecules enter host cells and inhibit the chemical pathways that viruses use to fold their proteins, including glucosidases in the endoplasmic reticulum that play a role in glycoprotein production. Because the iminosugars affect the host cell, rather than attacking the virus directly, they reduce the chance for drug-resistant virus strains to emerge. In laboratory tests, the iminosugar molecules have shown activity against several families of viruses.
Emergent and United Therapeutics
In January 2016, an Emergent Biosolutions representative stated that the Company has recently acquired UV-4B from United Therapeutics. Financial details were not disclosed.
Partners: United Therapeutics Corporation
Additional information available to subscribers only: